Covance Recognized with Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award
October 16 2017 - 8:45AM
Business Wire
LabCorp (NYSE: LH), a leading global life sciences company,
announced today that its Covance Drug Development business
(Covance) has been awarded the 2017 Frost & Sullivan Asia
Pacific CRO Customer Value Leadership Award. The award recognizes
Covance’s relentless focus on delivering value to customers by
offering drug development solutions that meet the unique
opportunities and needs of the Asia-Pacific biopharmaceutical
industry.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171016005631/en/
Covance employees accept Frost &
Sullivan Asia Pacific CRO Customer Value Leadership Award (Photo:
Business Wire)
“This honor demonstrates that our commitment and focus on Asia
Pacific is creating a distinctive advantage for our customers,”
said John Ratliff, CEO of Covance. “We have continued to expand our
drug development capabilities in Asia Pacific, from dedicated
nonclinical and clinical testing laboratories to clinical trial
operations, as well as unique regulatory and market access
solutions. In doing so, we have developed both deep local knowledge
and a track record of success of which we are very proud. I’d like
to thank our Asia-Pacific team for their dedication to our
customers and helping to advance our mission of improving health
and improving lives around the world.”
Covance established its presence in Asia Pacific in 1988 and has
continued to grow its comprehensive solutions in the region from
research to real world, including non-clinical development, central
laboratory services, clinical development and market access
solutions. Combining its global infrastructure, data analytics and
quality standards with local expertise and insight, Covance has
successfully created a tailored and relevant offering for the
Asia-Pacific market.
“Covance has a unique, integrated drug development portfolio
with informatics capabilities that enables biopharma clients to
reduce the cost of developing new drugs,” said Sanjeev Kumar,
industry manager, Healthcare Practice, Frost & Sullivan. “With
close to 30 years of experience in the Asian market, Covance serves
a wide range of customers by utilizing its experience in study
design, trial logistics, performance monitoring, clinical data
management and analytics to deliver the best services to
customers.”
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and uses technology
to improve the delivery of care. LabCorp reported net revenues of
nearly $9.5 billion for 2016. To learn more about LabCorp, visit
www.labcorp.com, and to learn more about Covance Drug Development,
visit www.covance.com.
This press release contains forward-looking statements about the
Company’s future operations. Each of the forward-looking statements
is subject to change based on various important factors, including
without limitation, competitive actions in the marketplace, and
adverse actions of governmental and other third-party payers.
Actual results could differ materially from those suggested by
these forward-looking statements. The Company has no obligation to
provide any updates to these forward-looking statements even if its
expectations change. Further information on potential factors that
could affect operating and financial results is included in the
Company’s Form 10-K for the year ended December 31, 2016, and
subsequent Forms 10-Q, including in each case under the heading
risk factors, and in the Company’s other filings with the SEC. The
information in this press release should be read in conjunction
with a review of the Company’s filings with the SEC including the
information in the Company’s Form 10-K for the year ended December
31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171016005631/en/
LabCorpMedia Contact:Sue Maynard,
+1-336-436-8263orInvestor Contact:Scott Frommer,
+1-336-436-5076
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024